Proposed Section Structure
This topic is best addressed through a clinically oriented structure that moves from disease context to pooled trial design, then to risk prediction, treatment effect, interpretation, and implications for practice. The article therefore uses the following sections: Highlights; Background; Study Design and Methods; Key Results; Mechanistic and Clinical Interpretation; Strengths and Limitations; Clinical Implications; Conclusion; Funding and Registration; References.
Highlights
Finerenone was associated with a 19% relative reduction in sudden death compared with placebo in a prespecified pooled analysis of three phase III trials spanning chronic kidney disease, type 2 diabetes, and heart failure.
Among 18,991 participants followed for a median of 2.9 years, 418 sudden deaths occurred, corresponding to 0.77 events per 100 patient-years.
Independent predictors of sudden death included older age, prior heart failure, atrial fibrillation, previous myocardial infarction, higher urine albumin-to-creatinine ratio, and lower systolic blood pressure at baseline.
The apparent benefit of finerenone was consistent across the number of baseline cardio-kidney-metabolic conditions and across the individual trials, supporting a potentially broad effect across the cardio-kidney-metabolic spectrum.
Background
Sudden death remains one of the most feared cardiovascular outcomes across the cardio-kidney-metabolic landscape. Patients with chronic kidney disease, type 2 diabetes, heart failure, or combinations of these disorders face a high burden of structural heart disease, autonomic dysfunction, myocardial fibrosis, vascular disease, electrolyte vulnerability, and progressive end-organ injury. In practice, these conditions rarely occur in isolation. Rather, they cluster in a mutually reinforcing syndrome that has increasingly been conceptualized as cardio-kidney-metabolic, or CKM, disease.
Despite substantial progress in reducing heart failure hospitalization and slowing kidney disease progression, sudden death has remained difficult to prevent in broad CKM populations. Traditional mineralocorticoid receptor antagonists such as spironolactone and eplerenone have established benefits in selected heart failure populations, but their use may be limited by hyperkalemia and tolerability concerns, especially in chronic kidney disease. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has already shown favorable effects on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes, and more recently in heart failure with mildly reduced or preserved ejection fraction.
What has been uncertain is whether these benefits extend specifically to sudden death. This question matters clinically because sudden death may reflect arrhythmic death, terminal pump failure misclassified as sudden death, or mixed mechanisms related to ischemia, fibrosis, congestion, and neurohormonal activation. Any signal that finerenone lowers sudden death would strengthen the case that mineralocorticoid receptor blockade favorably modifies the biology of CKM disease beyond conventional composite endpoints.
Study Design and Methods
Overview
This report was a prespecified FINE-HEART analysis that pooled participant-level data from three placebo-controlled phase III finerenone trials: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF. The analysis included 18,991 participants across a wide CKM spectrum.
Included trials and populations
FIDELIO-DKD and FIGARO-DKD enrolled patients with chronic kidney disease and type 2 diabetes. FINEARTS-HF enrolled patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction. Together, these trials create an unusually broad platform for examining outcomes that cut across renal, metabolic, and cardiovascular domains.
Endpoint definition
Sudden death was centrally adjudicated in each trial by a blinded clinical endpoint committee. This is an important methodological strength because sudden death can be difficult to classify reliably in large multicenter trials. Central adjudication reduces, although does not eliminate, outcome misclassification.
Statistical approach
The investigators identified clinical predictors of sudden death using multivariable Cox regression models. Treatment effects of finerenone versus placebo on sudden death were assessed using Cox models stratified by region and trial. The use of participant-level pooling rather than trial-level meta-analysis allows more granular modeling of covariates and subgroup consistency.
Key Results
Event rates
Among the 18,991 participants, 418 experienced sudden death, representing 2.2% of the pooled population over a median follow-up of 2.9 years. The overall incidence rate was 0.77 per 100 patient-years. This rate is clinically meaningful given the broad population studied and the fact that sudden death is often resistant to modification outside of highly selected populations.
The burden of sudden death was not uniform across trials. Rates were notably higher in FINEARTS-HF than in the chronic kidney disease trials, at 1.5 versus 0.5 per 100 patient-years. This difference is biologically plausible. Heart failure populations, even those with mildly reduced or preserved ejection fraction, carry heightened vulnerability to sudden death because of myocardial remodeling, fibrosis, atrial and ventricular arrhythmias, ischemic substrate, and competing nonarrhythmic cardiac mechanisms.
Predictors of sudden death
Several baseline characteristics emerged as independent predictors of sudden death in the pooled population. Higher risk was associated with older age, a history of heart failure, atrial fibrillation, prior myocardial infarction, higher urine albumin-to-creatinine ratio, and lower baseline systolic blood pressure.
These findings deserve emphasis because they bridge conventional cardiovascular risk markers with kidney disease severity. Older age, prior myocardial infarction, and atrial fibrillation identify patients with established myocardial disease and electrical instability. A history of heart failure adds risk related to chamber remodeling, fibrosis, and neurohormonal activation. Higher urine albumin-to-creatinine ratio is particularly important because it reinforces albuminuria not only as a kidney marker but also as a systemic vascular and endothelial risk signal. Lower systolic blood pressure likely reflects more advanced cardiac dysfunction, frailty, or limited hemodynamic reserve in some patients.
Treatment effect of finerenone
Randomization to finerenone was associated with a lower risk of sudden death compared with placebo, with a hazard ratio of 0.81 (95% CI, 0.67-0.98; P = 0.034). In relative terms, this corresponds to a 19% reduction in risk.
Although the absolute event rate was modest, sudden death is a high-consequence endpoint. A relative reduction of this magnitude is therefore clinically important, especially in a population spanning multiple CKM phenotypes. The confidence interval remained below 1.0, and the P value met conventional criteria for statistical significance, though the effect size should still be interpreted with the caution appropriate for an analysis of a less frequent secondary endpoint.
Consistency across subgroups
The relative risk reduction was consistent across subgroups defined by the number of baseline CKM conditions, with Pinteraction = 0.93. It was also consistent across the three trials, with Pinteraction = 0.71. These interaction results are reassuring because they suggest that the observed treatment effect is not driven solely by one disease state or one specific study population.
From a translational standpoint, this consistency supports the idea that mineralocorticoid receptor overactivation may be a shared pathogenic pathway across CKM disease. If so, finerenone may be acting on a common substrate that links kidney dysfunction, diabetes-related inflammation and fibrosis, and heart failure-related remodeling.
Mechanistic and Clinical Interpretation
Why might finerenone reduce sudden death?
The present analysis was not designed to establish mechanism, but several biologically plausible explanations exist. Mineralocorticoid receptor activation contributes to myocardial fibrosis, inflammation, endothelial dysfunction, oxidative stress, and adverse ventricular remodeling. These processes may promote arrhythmogenesis and increase vulnerability to fatal cardiac events. By attenuating these pathways, finerenone could theoretically reduce arrhythmic substrate and stabilize the myocardium.
Finerenone may also lower sudden death indirectly by reducing progression of heart failure, decreasing congestion, and improving cardiorenal interactions. In CKM disease, even nonarrhythmic pathways can culminate in unexpected circulatory collapse that may be adjudicated as sudden death in trial settings. Thus, the treatment effect could represent a combined anti-fibrotic, hemodynamic, and systemic organ-protective signal.
How does this fit with prior finerenone evidence?
Previous phase III trials established finerenone as an effective therapy for reducing cardiovascular and kidney events in chronic kidney disease with type 2 diabetes. The FINEARTS-HF program extended benefit into heart failure with mildly reduced or preserved ejection fraction. What the current FINE-HEART analysis adds is a focused look at sudden death, an endpoint that is both clinically meaningful and mechanistically informative.
Importantly, the finding aligns with a broader understanding of mineralocorticoid receptor antagonism in cardiovascular disease, while extending it to a nonsteroidal agent used across a wider cardiorenal population. This is especially relevant in patients with chronic kidney disease, where clinicians often seek effective therapies that balance efficacy with potassium-related safety.
Strengths and Limitations
Strengths
The study has several strengths. First, it was prespecified, which reduces concerns about purely exploratory post hoc inference. Second, it pooled participant-level data from three large, placebo-controlled trials, improving statistical power and allowing harmonized modeling. Third, sudden death was centrally adjudicated by blinded committees, an essential feature for outcome credibility. Fourth, the analysis examined both predictors of sudden death and treatment effect, making it clinically useful for risk stratification as well as therapy assessment.
Limitations
Several limitations should temper interpretation. Sudden death remains a difficult endpoint to classify with precision, even in well-run trials. Some deaths categorized as sudden may represent unwitnessed nonarrhythmic death, terminal heart failure, stroke, or other mechanisms. Second, despite the large pooled sample, the number of sudden death events was still modest relative to the total population, which limits precision. Third, the trials enrolled selected patients under protocolized conditions; generalizability to broader real-world CKM populations, including those with more advanced frailty or different concomitant therapies, requires confirmation. Fourth, this pooled analysis cannot fully determine whether the apparent benefit differs by background use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, implantable devices, or antiarrhythmic strategies.
Finally, the report demonstrates association based on randomized assignment, but it does not establish the exact pathway through which sudden death risk was reduced. Further mechanistic and electrophysiologic work would be valuable.
Clinical Implications
For clinicians managing CKM disease, these findings reinforce several practical themes. First, sudden death risk is not confined to classic reduced ejection fraction heart failure. It is present across chronic kidney disease, diabetes, and preserved or mildly reduced ejection fraction heart failure, particularly when these conditions cluster. Second, markers such as albuminuria, prior myocardial infarction, atrial fibrillation, heart failure history, and lower systolic blood pressure may help identify patients at elevated risk.
Third, finerenone’s benefits may extend beyond conventional composite outcomes such as kidney disease progression or hospitalization. A possible reduction in sudden death increases the treatment’s clinical relevance, particularly when discussing expected benefits with patients and multidisciplinary teams.
That said, finerenone should still be used within its approved clinical context and with attention to renal function and serum potassium monitoring. The present analysis strengthens its value proposition but does not replace individualized treatment decisions. In modern CKM care, finerenone is likely best understood as part of a layered strategy alongside renin-angiotensin system blockade, glucose-lowering therapies with cardiovascular and renal benefit, blood pressure control, and heart failure-directed management where indicated.
Conclusion
The FINE-HEART analysis provides important evidence that finerenone may reduce sudden death across the cardio-kidney-metabolic spectrum. In a pooled cohort of 18,991 participants from three major placebo-controlled trials, finerenone was associated with a statistically significant 19% relative reduction in sudden death, with consistent effects across trials and across different burdens of CKM disease.
Equally important, the analysis clarifies the clinical profile associated with higher sudden death risk: older age, heart failure, atrial fibrillation, prior myocardial infarction, greater albuminuria, and lower systolic blood pressure. These features underscore the interconnected biology of CKM disease and support a more integrated approach to risk assessment.
While further work is needed to define mechanisms, validate findings in real-world populations, and understand interactions with contemporary CKM therapies, the present study meaningfully extends the therapeutic narrative for finerenone. It suggests that nonsteroidal mineralocorticoid receptor antagonism may influence one of the most serious outcomes in cardio-renal medicine: sudden death.
Funding and Registration
The abstract identifies this work as FINE-HEART: An Integrated Pooled Analysis of Finerenone across 3 Phase III Trials of Heart Failure and Chronic Kidney Disease and Type 2 Diabetes, registered as CRD42024570467. Specific funding details were not provided in the supplied abstract and should be confirmed from the full publication.
References
1. Foà A, Pabon MA, Filippatos G, Claggett BL, Miao ZM, Jhund PS, Henderson A, Brinker M, Lage A, Hofmeister L, De Sanctis Y, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M, Desai AS. Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis. Journal of the American College of Cardiology. 2026-06-03. PMID: 42233928. https://pubmed.ncbi.nlm.nih.gov/42233928/
2. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Filippatos G. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2020;383:2219-2229.
3. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 2021;385:2252-2263.
4. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Shah SJ, Zannad F. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. 2024;390:1389-1400.